Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Data in Resected Colorectal Cancer Liver Metastases

May 2nd 2024

Louise Catherine Connell, MB BCh BAO, BMedSc, and Ryan Merkow, MD, MS, review clinical trial data on resected colorectal cancer liver metastases.

Hepatic Artery Infusion Data in Unresectable Colorectal Cancer Liver Metastases

May 2nd 2024

A surgical oncologist and gastrointestinal oncologist review data on hepatic artery infusion therapy in unresectable colorectal cancer liver metastases.

Hepatic Artery Infusion Background

May 2nd 2024

Two experts on gastrointestinal cancers give a broad overview of hepatic artery infusions.

Unmet Needs in Colorectal Cancer Liver Metastases

May 2nd 2024

Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, discuss the current treatment landscape in colorectal cancer liver metastases, highlighting unmet needs in the treatment space.

Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer

May 1st 2024

Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer

April 30th 2024

Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

April 29th 2024

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

Monitoring and AE Management Strategies with Fruquintinib in CRC

April 25th 2024

Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib.

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

April 25th 2024

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer

April 25th 2024

CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.

FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs

April 23rd 2024

The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR–positive GEP-NETs.

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024

Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

First-Line Pembrolizumab Plus Chemo Wins Canadian Approval for HER2– Advanced Gastric/GEJ Adenocarcinoma

April 19th 2024

Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.

Durvalumab Plus Chemo Sustains 3-Year OS Benefit in Advanced Biliary Tract Cancer

April 16th 2024

Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.

Trajectory of Evolving HCC Treatment Landscape

April 15th 2024

The expert panelists provide their final insights surrounding the future of HCC treatment management.

REGONEXT Study: Driving Second-line HCC Treatment Strategy

April 15th 2024

Dr Morse discusses key takeaways from the REGONEXT study presented at ASCO GI 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

April 11th 2024

John Strickler, MD, presents the case of a 62-year-old woman with rectal cancer, and Arvind N. Dasari, MD, MS, provides clinical insights on his approach to third-line treatment with regorafenib, highlighting dose strategy and patient education.

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

April 11th 2024

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.